JP2020515236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515236A5 JP2020515236A5 JP2019537282A JP2019537282A JP2020515236A5 JP 2020515236 A5 JP2020515236 A5 JP 2020515236A5 JP 2019537282 A JP2019537282 A JP 2019537282A JP 2019537282 A JP2019537282 A JP 2019537282A JP 2020515236 A5 JP2020515236 A5 JP 2020515236A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- composition
- cells
- epigenetic
- genomic regions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 90
- 239000000203 mixture Substances 0.000 claims 68
- 238000000034 method Methods 0.000 claims 51
- 230000001973 epigenetic effect Effects 0.000 claims 35
- 108010077544 Chromatin Proteins 0.000 claims 19
- 210000003483 chromatin Anatomy 0.000 claims 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims 18
- 108020003175 receptors Proteins 0.000 claims 18
- 102000005962 receptors Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 230000004044 response Effects 0.000 claims 8
- 238000004458 analytical method Methods 0.000 claims 7
- 238000002659 cell therapy Methods 0.000 claims 6
- 230000006870 function Effects 0.000 claims 6
- 206010052015 cytokine release syndrome Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108091027963 non-coding RNA Proteins 0.000 claims 4
- 102000042567 non-coding RNA Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- 230000001988 toxicity Effects 0.000 claims 4
- 231100000419 toxicity Toxicity 0.000 claims 4
- 206010029350 Neurotoxicity Diseases 0.000 claims 3
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 3
- 108700019146 Transgenes Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- 230000007135 neurotoxicity Effects 0.000 claims 3
- 231100000228 neurotoxicity Toxicity 0.000 claims 3
- 230000002688 persistence Effects 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108010047956 Nucleosomes Proteins 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 230000004570 RNA-binding Effects 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000012165 high-throughput sequencing Methods 0.000 claims 2
- 230000010354 integration Effects 0.000 claims 2
- 238000013507 mapping Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 210000001623 nucleosome Anatomy 0.000 claims 2
- 238000000513 principal component analysis Methods 0.000 claims 2
- 230000008569 process Effects 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 1
- 108091032955 Bacterial small RNA Proteins 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 108091062157 Cis-regulatory element Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 230000007067 DNA methylation Effects 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108010034791 Heterochromatin Proteins 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091029795 Intergenic region Proteins 0.000 claims 1
- 108020005198 Long Noncoding RNA Proteins 0.000 claims 1
- 108091092724 Noncoding DNA Proteins 0.000 claims 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 claims 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 102000008579 Transposases Human genes 0.000 claims 1
- 108010020764 Transposases Proteins 0.000 claims 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000008236 biological pathway Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000002487 chromatin immunoprecipitation Methods 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 claims 1
- 238000005138 cryopreservation Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 210000004458 heterochromatin Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000037353 metabolic pathway Effects 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 238000003068 pathway analysis Methods 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 208000037821 progressive disease Diseases 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 108091035539 telomere Proteins 0.000 claims 1
- 210000003411 telomere Anatomy 0.000 claims 1
- 102000055501 telomere Human genes 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000005030 transcription termination Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444802P | 2017-01-10 | 2017-01-10 | |
| US62/444,802 | 2017-01-10 | ||
| US201762551752P | 2017-08-29 | 2017-08-29 | |
| US62/551,752 | 2017-08-29 | ||
| US201762596662P | 2017-12-08 | 2017-12-08 | |
| US62/596,662 | 2017-12-08 | ||
| PCT/US2018/013227 WO2018132518A1 (en) | 2017-01-10 | 2018-01-10 | Epigenetic analysis of cell therapy and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515236A JP2020515236A (ja) | 2020-05-28 |
| JP2020515236A5 true JP2020515236A5 (enExample) | 2021-02-25 |
| JP7429338B2 JP7429338B2 (ja) | 2024-02-08 |
Family
ID=61198889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537282A Active JP7429338B2 (ja) | 2017-01-10 | 2018-01-10 | 細胞療法および関連方法のエピジェネティック解析 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11821027B2 (enExample) |
| EP (1) | EP3568414A1 (enExample) |
| JP (1) | JP7429338B2 (enExample) |
| CN (1) | CN110691792A (enExample) |
| AU (1) | AU2018207305A1 (enExample) |
| CA (1) | CA3049461A1 (enExample) |
| MA (1) | MA47283A (enExample) |
| MX (1) | MX2019008227A (enExample) |
| WO (1) | WO2018132518A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11519033B2 (en) * | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
| JP7549582B2 (ja) * | 2018-10-01 | 2024-09-11 | ロンザ リミテッド | 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法 |
| WO2020198942A1 (zh) * | 2019-03-29 | 2020-10-08 | 中国科学技术大学 | 基于峰聚类的单细胞染色质可及性测序数据分析方法和系统 |
| EP4104177A1 (en) * | 2020-02-13 | 2022-12-21 | 10X Genomics, Inc. | Methods for characterizing cells using gene expression and chromatin accessibility |
| CN113436683B (zh) * | 2020-03-23 | 2024-08-16 | 北京合生基因科技有限公司 | 筛选候选插入片段的方法和系统 |
| WO2023069985A1 (en) * | 2021-10-19 | 2023-04-27 | Battelle Memorial Institute | Technologies for genetic engineering detection |
| EP4659248A1 (en) * | 2023-01-31 | 2025-12-10 | Guardant Health, Inc. | Non-invasive monitoring of genomic alterations induced by gene-editing therapies |
| CN117286229B (zh) * | 2023-11-23 | 2024-05-03 | 中山大学中山眼科中心 | 一种mhc区域三维基因组结构的高通量长读长测序方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| RU2149023C1 (ru) | 1998-04-20 | 2000-05-20 | Ерхов Валентин Сергеевич | Способ получения специфической антисыворотки к универсальному опухолевому антигену и способ диагностики злокачественных опухолей с использованием этой антисыворотки |
| DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| JP4317940B2 (ja) | 2001-08-31 | 2009-08-19 | イミュノコア・リミテッド | 物質 |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| TWI460602B (zh) | 2008-05-16 | 2014-11-11 | Counsyl Inc | 廣用的懷孕前篩檢裝置 |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| US9080211B2 (en) | 2008-10-24 | 2015-07-14 | Epicentre Technologies Corporation | Transposon end compositions and methods for modifying nucleic acids |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| JP6082997B2 (ja) | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| CA2864192C (en) | 2012-03-12 | 2022-06-21 | Epiontis Gmbh | Epigenetic marker for the identification of cd3cd4 positive t lymphocytes |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| US9092401B2 (en) | 2012-10-31 | 2015-07-28 | Counsyl, Inc. | System and methods for detecting genetic variation |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2014189957A2 (en) | 2013-05-23 | 2014-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Transposition into native chromatin for personal epigenomics |
| CA2929249A1 (en) | 2013-11-13 | 2015-05-21 | Counsyl, Inc. | Automated nucleic acid repeat count calling methods |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| SG11201605259QA (en) | 2013-12-30 | 2016-07-28 | Agency Science Tech & Res | Methods for measuring biomarkers in gastrointestinal cancer |
| AU2015222944A1 (en) | 2014-02-27 | 2016-09-08 | Massachusetts Institute Of Technology | T cell balance gene expression, compositions of matters and methods of use thereof |
| EP3132057B1 (en) | 2014-04-17 | 2019-10-16 | Yeda Research and Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
| EP4008725A1 (en) | 2014-05-02 | 2022-06-08 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| US20170211143A1 (en) | 2014-07-25 | 2017-07-27 | University Of Washington | Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same |
| CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| US20160140289A1 (en) | 2014-10-16 | 2016-05-19 | Counsyl, Inc. | Variant caller |
| EP3031929A1 (en) | 2014-12-11 | 2016-06-15 | Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch | Genome architecture mapping |
| CN107710185A (zh) | 2015-06-22 | 2018-02-16 | 康希尔公司 | 预测基因序列变异的致病性的方法 |
| MX2018003353A (es) * | 2015-09-17 | 2018-09-17 | Novartis Ag | Terapias con celulas cart con una eficacia mejorada. |
| US9678850B1 (en) | 2016-06-10 | 2017-06-13 | Palantir Technologies Inc. | Data pipeline monitoring |
| WO2017218908A2 (en) | 2016-06-16 | 2017-12-21 | The Johns Hopkins University | Methods and system for epigenetic analysis |
| CA3061945A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
-
2018
- 2018-01-10 US US16/476,856 patent/US11821027B2/en active Active
- 2018-01-10 CN CN201880016199.3A patent/CN110691792A/zh active Pending
- 2018-01-10 EP EP18705031.5A patent/EP3568414A1/en active Pending
- 2018-01-10 AU AU2018207305A patent/AU2018207305A1/en not_active Abandoned
- 2018-01-10 CA CA3049461A patent/CA3049461A1/en active Pending
- 2018-01-10 MX MX2019008227A patent/MX2019008227A/es unknown
- 2018-01-10 WO PCT/US2018/013227 patent/WO2018132518A1/en not_active Ceased
- 2018-01-10 JP JP2019537282A patent/JP7429338B2/ja active Active
-
2019
- 2019-10-28 MA MA047283A patent/MA47283A/fr unknown
-
2023
- 2023-10-17 US US18/488,850 patent/US20240158837A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515236A5 (enExample) | ||
| Gulhati et al. | Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer | |
| JP7772739B2 (ja) | 個別化治療を決定するための方法およびシステム | |
| Lambrechts et al. | Phenotype molding of stromal cells in the lung tumor microenvironment | |
| Herglotz et al. | Essential control of early B-cell development by Mef2 transcription factors | |
| Denk et al. | Persistent alterations in microglial enhancers in a model of chronic pain | |
| Wu et al. | Research techniques made simple: single-cell RNA sequencing and its applications in dermatology | |
| US7198895B2 (en) | In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals | |
| ES2541934T5 (es) | Procedimientos de identificación de un anticuerpo o una diana | |
| Meednu et al. | Dynamic spectrum of ectopic lymphoid B cell activation and hypermutation in the RA synovium characterized by NR4A nuclear receptor expression | |
| JP2021501318A (ja) | 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 | |
| Matchett et al. | Spatial genomics: mapping human steatotic liver disease | |
| KR20220156849A (ko) | 단일 세포의 진화를 추적하는 시스템 및 방법 | |
| Rafei et al. | CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells | |
| Paprckova et al. | Narcissistic T cells: reactivity to self makes a difference | |
| CA3175622A1 (en) | Modulation of t cell cytotoxicity and related therapy | |
| Zhang et al. | TEAD4 antagonizes cellular senescence by remodeling chromatin accessibility at enhancer regions | |
| US20220000893A1 (en) | Method for treating t-helper type 2 mediated disease | |
| Pai et al. | Regional and clonal T cell dynamics at single cell resolution in immune checkpoint blockade | |
| Georgakis et al. | Cellular and molecular determinants mediating the dysregulated germinal center immune dynamics in systemic lupus erythematosus | |
| Higgins | Programming isotype specific plasma cell differentiation | |
| Isbell et al. | Patient‐derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphoma | |
| US20190144937A1 (en) | Novel methods for quantifying proteins using phage-based sequencing | |
| US20250230243A1 (en) | Prediction of chemotherapy-free immunotherapy effectiveness for patients with cancers | |
| Chikarmane | Coordinated Activation of the Androgen Receptor Transcriptional Program in Prostate Cancer |